About Biogen Inc. (BIIB)

Company Description:

Biogen Inc., a pioneering biopharmaceutical company, is significantly involved in the discovery, development, and delivery of innovative therapies for treating neurological and neurodegenerative diseases. It operates primarily in the Drug Manufacturers – General industry within the Healthcare sector.

Biogen was founded in 1978 by several eminent biologists, including Nobel Prize winners Walter Gilbert and Phillip Sharp. The company is headquartered in Cambridge, Massachusetts, United States, and has been a leader in neuroscience research and treatment advancements.

Main Product(s):

Biogen's portfolio mainly focuses on treatments for multiple sclerosis and neurodegenerative diseases, including therapies like Tecfidera, Avonex, and Tysabri for multiple sclerosis, and Spinraza for spinal muscular atrophy. The company also has a growing pipeline of potential therapies for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Short History of Biogen Inc.:

• 1978 – Biogen was founded by a group of scientists including Nobel laureates.
• 1983 – Biogen went public.
• 2003 – Merged with Idec Pharmaceuticals, focusing more on neurology.
• 2015 – Announced restructuring to focus more on neurodegenerative diseases.
• 2020 – Received FDA approval for its Alzheimer's disease drug, Aduhelm.